Loading viewer...
earnings
Format: PDF earnings
Natera reported record Q1 2024 performance with $367.7M in revenue (52% YoY growth) and achieved cash flow breakeven a quarter earlier than expected. The genomic testing company raised 2024 guidance to $1.42B-$1.45B in revenue with 53-55% gross margins, while advancing its portfolio across oncology, transplant, and prenatal diagnostics.
earnings
17 Pages
earnings
52 Pages
Teva Pharmaceutical Industries Ltd.